Madan Jagasia

Company: Obsidian Therapeutics

Job title: Chief Executive Officer

Seminars:

OBX-115 Engineered TIL Cell Therapy with Regulatable Membrane-Bound IL15: Initial Multicenter Clinical Trial Results in Advanced Melanoma 8:50 am

OBX-115 TIL is engineered to express membrane-bound IL15 regulated by acetazolamide, abrogating the need for IL2 OBX-115 is compatible with low-dose lymphodepletion and has a positively differentiated safety profile At RP2D, OBX-115 can induce deep and durable responses in patients with ICIresistant advanced melanomaRead more

day: Conference Day One AM

Fireside Chat: Clinical Data & Reflections on the Current State of TIL Therapies in the Clinic 9:30 am

Examining the latest clinical insights shaping TIL therapy to better understand the direction of innovation in the field Discussing real-world challenges and opportunities in TIL development to uncover practical strategies for accelerating progress Envisioning the future of TIL therapies through expert perspectives to inform more effective research and clinical decisionsRead more

day: Conference Day One AM